Association of previously irradiated stable brain metastases with outcomes of atezolizumab-treated non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trials

作     者：Tiantian Guo Yue Zhou Fei Liang Zezhou Wang Vincent Bourbonne Lukas Käsmann Nora Sundahl Abraham Jing-Ching Wu Jianjiao Ni Zhengfei Zhu 

作者机构：Department of Radiation OncologyFudan University Shanghai Cancer CenterShanghaiP.R.China Department of OncologyShanghai Medical CollegeFudan UniversityShanghaiP.R.China Shanghai Clinical Research Center for Radiation OncologyShanghaiP.R.China Shanghai Key Laboratory of Radiation OncologyShanghaiP.R.China Department of BiostatisticsZhongshan HospitalFudan UniversityShanghaiP.R.China Department of Cancer PreventionFudan University Shanghai Cancer CenterShanghaiP.R.China Radiation Oncology DepartmentUniversity HospitalBrestFrance Department of Radiation OncologyUniversity HospitalLMU MunichMunichGermany Department of Radiation OncologyAZ GroeningeKortrijkBelgium Department of Radiation OncologyMemorial Sloan Kettering Cancer CenterNew YorkNew YorkUSA Institute of Thoracic OncologyFudan UniversityShanghaiP.R.China 

出 版 物：《Cancer Communications》 (癌症通讯（英文）)

年 卷 期：2024年第44卷第2期

页      面：278-281页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Chinese Society of Clinical Oncology AME Lung Cancer Collaborative Group 

主　　题：chemotherapy NSCLC metastasis death 

摘      要：Dear Editor:Brain metastasis(BM)has long been recognized as a prognostic factor associated with poor prognosis for non-small cell lung cancer(NSCLC)in the era of con-ventional chemotherapy and targeted therapy[1].In the era of immunotherapy,controversial findings have been reported regarding the prognostic significance of BM in patients with NSCLC treated with programmed death-1/programmed death-ligand 1(PD-1/PD-L1)inhibitors.